Phase III, Study of Three Short Course Combo (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome for the Treatment of VL in Bangladesh

Mise à jour : Il y a 4 ans
Référence : NCT01122771

Femme et Homme

  • | Pays :
  • Bangladesh
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

This protocol will evaluate the efficacy and safety of various combinations of the three drugs; AmBisome, Paromomycin and Miltefosine at reduced total dosage against the standard treatment with a total dose of 15mg/kg of AmBisome.


Critère d'inclusion

  • Visceral leishmaniasis

Liens